Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more
Chi-Med, Inmagene partner on immunological indications
Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) granted Inmagene Biopharmaceuticals Co. Ltd. exclusive options to four immunological diseases programs for up to $95 million in development milestones, $135 million in commercial milestones plus up to double-digit royalties. The partners will collaborate on work funded by Inmagene to support IND submission; if successful, Inmagene will be responsible for global clinical development.
Zai Lab adds another Turning Point program to stable of targeted oncology assets
On Monday Turning Point Therapeutics Inc. (NASDAQ:TPTX) granted Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) exclusive Chinese rights to TPX-0022 for $25 million up front and up to $336 million in milestones. The small molecule inhibitor of c-MET, CSF1R and Src is in Phase I testing to treat c-MET-positive solid tumors. Last July Zai licensed Chinese rights to Turning Point’s lead program repotrectinib for the same up front sum...